STM-416p
Phase 1Small molecule
STM-416p is one of 11 small molecule programs targeting Prostatectomy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Prostatectomy
#DrugCompanyPhaseTrials
1Leuprorelin
TakedaPhase 3
Sutent
PfizerPhase 2
Firmagon
FerringPhase 2
LHRH Agonist
RochePhase 2
Flomax
SanofiPreclinical
Ramosetron
AstellasPreclinical
ARN-509
AAragon Pharmaceuticals, Inc.
Phase 2
STM-416p
SSURGE Therapeutics
Phase 1
Vesicare
AstellasPreclinical
Acetaminophen/ibuprofen
SSeoul National University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for STM-416p. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSURGE Therapeutics